24 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
is an oral candidate, a well-defined clinical target, and clinical & regulatory programs underpinned by a biomarker strategy. The How: Strong community
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
the community is commemorating Alzheimer’s & Brain Awareness Month. During June in particular we recognize the challenges of Alzheimer’s and other
424B4
4v274ps
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
0wa0sor5p0oeami8awdj
20 Oct 22
Draft registration statement
12:00am
DEF 14A
fce0hacq6etj8d2rq
25 Apr 22
Definitive proxy
5:28pm
10-K
ipzdo 5v7908mcmqi75
30 Mar 22
Annual report
7:40am
10-Q
jxtlmvjycz6hfw6
17 Nov 21
Quarterly report
5:15pm
424B4
zzu88k9jklm
12 Oct 21
Prospectus supplement with pricing info
4:11pm
CORRESP
ca1iuv 860
29 Jul 21
Correspondence with SEC
12:00am
S-1
EX-10.4
vzkd4j30d4795
19 Jul 21
IPO registration
7:02am
S-1
EX-10.15
bw9soxrfpz7za28rph
19 Jul 21
IPO registration
7:02am
S-1
s2j0t1n
19 Jul 21
IPO registration
7:02am